Moderna
Oct 21, 2026

Moderna jumps 11% in two sessions as whale short nears liquidation before cancer data release

Moderna shares extended their rebound ahead of a closely watched cancer therapy data presentation, rising 4.07% and 6.69% over the past two U.S. trading sessions for a combined gain of about 11.04%. The stock last closed at $242.08 and touched an intraday high of $243.98, while the corresponding Hyperliquid contract traded at $241.07, up about 5.71% over 24 hours. The move comes before detailed Phase 3 results for intismeran autogene, the personalized mRNA cancer therapy Moderna is developing with Merck, are scheduled to be presented at the European Society for Medical Oncology meeting on Oct. 24 at 22:30 Beijing time, followed by an investor event at 01:00 on Oct. 25. The companies had said on Aug. 19 that the therapy in combination with Keytruda met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. TradingBeats data also showed a whale address beginning with 0x4e23 holding a roughly $4.518 million 10x isolated short in MRNA on Hyperliquid, with an estimated liquidation price of $248.37.

1210
Moderna jumps 11% in two sessions as whale short nears liquidation before cancer data release